Clinical Observation on Shengxue Pills（生血丸） in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression

ZHANG Lili; ZHAO Linlin; LI Xiaojiang; YANG Peiying; CHEN Liang; YU Jianchun

doi:10.13288/j.11-2166/r.2014.13.013

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Shengxue Pills（生血丸） in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression

更新时间：2021-11-17

- Clinical Observation on Shengxue Pills（生血丸） in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression
- Journal of Traditional Chinese Medicine Vol. 55, Issue 13, Pages: 1123-1126(2014)
- 作者机构：
  
  天津中医药大学第一附属医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2014.13.013
  CLC： R730.5
- Published：2014
- 稿件说明：
移动端阅览
[1]张丽丽,赵林林,李小江,杨佩颖,陈亮,于建春.生血丸防治化疗所致骨髓抑制32例临床观察[J].中医杂志,2014,55(13):1123-1126.

ZHANG Lili, ZHAO Linlin, LI Xiaojiang, et al. Clinical Observation on Shengxue Pills（生血丸） in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression[J]. Journal of Traditional Chinese Medicine2014, 55(13): 1123-1126.
[1]张丽丽,赵林林,李小江,杨佩颖,陈亮,于建春.生血丸防治化疗所致骨髓抑制32例临床观察[J].中医杂志,2014,55(13):1123-1126. DOI： 10.13288/j.11-2166/r.2014.13.013.

ZHANG Lili, ZHAO Linlin, LI Xiaojiang, et al. Clinical Observation on Shengxue Pills（生血丸） in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression[J]. Journal of Traditional Chinese Medicine2014, 55(13): 1123-1126. DOI： 10.13288/j.11-2166/r.2014.13.013.

摘要

目的观察生血丸对化疗所致骨髓抑制的临床疗效。方法将64例确诊为非小细胞肺癌、肠癌、胃癌、乳腺癌的肿瘤患者随机分为治疗组和对照组各32例

两组均给予常规剂量化疗方案。治疗组于化疗前7天开始口服生血丸;对照组于化疗前7天开始口服益血生胶囊

两组均以28天为1个疗程。于治疗前及治疗第7、14、21天检测两组血常规

包括白细胞（WBC）、血红蛋白（HGB）、血小板（PLT）;于治疗前后检测免疫功能指标

即T细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+）、NK细胞、白细胞介素-2（IL-2）、白细胞介素-10（IL-10）、γ干扰素（INF-γ）水平

并进行临床症状积分、卡氏评分（KPS）。结果与治疗前比较

化疗第7天

对照组WBC显著下降（P<0.05）;两组化疗第21天与治疗前比较

WBC均明显升高（P<0.05）

治疗组高于对照组（P<0.05）。治疗后治疗组CD3+、CD4+、CD4+/CD8+较治疗前明显升高（P<0.05）;对照组CD3+、NK较治疗前明显升高（P<0.05）;治疗组治疗后CD4+、CD4+/CD8+水平高于对照组（P<0.05）。与治疗前比较

治疗后两组IL-2、INF-γ水平均有所上升（P<0.05）。两组临床症状积分治疗后均较治疗前降低（P<0.01）;治疗后两组KPS评分均较治疗前上升（P<0.05）;治疗后两组KPS评分及临床症状积分比较差异均无统计学意义（P>0.05）。结论生血丸具有保护骨髓造血功能、提高机体免疫功能、改善临床症状及提高生活质量的作用

且对提高CD4+、CD4+/CD8+水平效果优于益血生胶囊。

Abstract

Objective To observe the efficacy of Shengxue Pills（pills to promote the production of blood

生血丸）for chemotherapy-induced myelosuppression. Methods Totally 64cases of non-small cell lung cancer

colon cancer

stomach cancer and breast cancer were randomized into the treatment group and control group

with 32in each.Both groups were given conventional chemotherapy.The patients in the treatment group began to taken Shengxue Pills 7days before chemotherapy

while the patients in the control group were given Yixuesheng Capsules（益血生）.One treatment course lasted for 28days.The counts of white blood cell（WBC）

hemoglobin（HGB）and platelet（PLT）were detected before treatment and on the 7th

14th and 21st day of treatment in both groups.The levels of CD3+

CD4+

CD8+

CD4+/CD8+

natural killer（NK）cells

interleukin-2（IL-2）

IL-10and interferon-γ（INF-γ）were detected before and after treatment.The scores of symptoms and Karnofsky performance status（KPS）were observed. Results The count of WBC was significantly decreased in the control group on the 7th day of chemotherapy（P<0.05）.The counts of WBC were significantly increased in both groups on 21st day of chemotherapy（P<0.05）

especially in the treatment group（P<0.05）.The levels of CD3+

CD4+and CD4+/CD8+were significantly increased in the treatment group（P<0.05）.The levels of CD3+and NK cells were significantly increased in the control group（P<0.05）.Comparing with the control group

the levels of CD4+and CD4+/CD8+were significantly increased in the treatment group（P<0.05）.The levels of IL-2and INF-γwere significantly increased in both groups after treatment（P<0.05）.The symptom scores were significantly decreased in both groups after treatment（P<0.01）.The scores of KPS were significantly increased in both groups after treatment（P<0.05）.There was no significant difference between groups in the scores of symptoms and KPS after treatment（P>0.05）. Conclusion Shengxue Pills can protect bone marrow function

enhance immune function

relieve clinical symptoms and improve quality of life

with a better efficacy in increasing the levels of CD4+and CD4+/CD8+as compared with Yixuesheng Capsules.

关键词

Keywords

references

查看原文

Views

223

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Yisui Shengxue Pills （益髓生血丸） as Adjuvant Treatment for Myelosuppression after Chemotherapy for 40 Patients of Malignant Tumours with Qi and Yin Deficiency Syndrome：A Randomised Controlled Trial

Discussion on Body Resistance-Strengthening,Toxin-Resolving and Stasis-Dispelling Therapy for Chemotherapy-Induced Myelosuppression

Effect of Heat-sensitive Moxibustion on Quality of Life and Immune Function in Non-Small Cell Lung Cancer Patients with Qi Deficiency and Phlegm Stasis Syndrome Undergoing Chemotherapy：A Randomized Controlled Trial

Effects of Moxibustion on Ginger Combined with High Tryptophan Diet on Clinical Efficacy and Immune Function in Chronic Fatigue Syndrome Patients with Spleen-Kidney Yang Deficiency：A Randomized Controlled Trial

Effect of Qingfei Shenshi Decoction （清肺渗湿汤） Combined with Western Medicine on Clinical Effectiveness and Immune Function for Patients with Bronchial Asthma of Heat Wheezing Syndrome

Related Author

JIAO Ning

ZHANG Dengshan

SHI Lina

MAO Mao

TAN Guochang

JIA Yingjie

YU Jianchun

YANG Peiying

Related Institution

Hospital of Traditional Chinese Medicine of Zibo City

Tianjin University of Traditional Chinese Medicine

Jinan Vocational College of Nurisng，Shandong Pronvince

Guangdong Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Guangzhou University of Chinese Medicine

Henan Province Hospital of Traditional Chinese Medicine/The Second Affiliated Hospital of Henan University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰